A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

LONDON (Reuters) -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

Eli Lilly(NYSE: LLY ... but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly. Let's look deeper into the pharmaceutical ...

Eli Lilly's oral GLP-1 medicine aced a phase ... but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.

Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. The lawsuits ...